{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:20:09Z","timestamp":1792819209284,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Biliary-tract-carcinomas (BTC), pancreatic-ductal-adenocarcinomas (PDAC) and adenoidcystic-carcinomas (AC) have in common that they are traditionally treated with large clinical-target-volumes (CTV). The aim of this study is to examine the impact of pretreatment-[<jats:sup>68<\/jats:sup>Ga]FAPI-PET\/CT on target-volume-definition and posttreatment-[<jats:sup>68<\/jats:sup>Ga]FAPI-PET\/CT-response-assessment for BTC-, PDAC- and AC-patients referred to radiation-therapy. All consecutive BTC-, PDAC-, and AC-patients who received pretreatment-[<jats:sup>68<\/jats:sup>Ga]FAPI-PET\/CT\u00b1[<jats:sup>18<\/jats:sup>F]FDG-PET\/CT were included from 01.01.2020 to 01.03.2022. MTV and SUV<jats:sub>max<\/jats:sub> were separately generated based on [<jats:sup>68<\/jats:sup>Ga]FAPI- and [<jats:sup>18<\/jats:sup>F]FDG-PET\/CT-images. A [<jats:sup>68<\/jats:sup>Ga]FAPI- and [<jats:sup>18<\/jats:sup>F]FDG-based-CTV was defined. Treatment-plans were compared. Treatment-response was reassessed by a second [<jats:sup>68<\/jats:sup>Ga]FAPI-PET\/CT and [<jats:sup>18<\/jats:sup>F]FDG-PET\/CT after treatment-completion. Intermodality comparison of lesion-to-background-ratios [SUV<jats:sub>max_lesion<\/jats:sub>\/SUV<jats:sub>mean_background<\/jats:sub>] for individual timepoints <jats:italic>t<\/jats:italic><jats:sub><jats:italic>1<\/jats:italic><\/jats:sub> and <jats:italic>t<\/jats:italic><jats:sub><jats:italic>2<\/jats:italic><\/jats:sub> revealed significant higher values for [<jats:sup>68<\/jats:sup>Ga]FAPI compared to [<jats:sup>18<\/jats:sup>F]FDG (<jats:italic>t<\/jats:italic><jats:sub><jats:italic>1<\/jats:italic><\/jats:sub>, <jats:italic>p<\/jats:italic>\u2009=\u20090.008; <jats:italic>t<\/jats:italic><jats:sub><jats:italic>2<\/jats:italic><\/jats:sub>, <jats:italic>p<\/jats:italic>\u2009=\u20090.005). Intermodality comparison of radiation-therapy-plans showed that [<jats:sup>68<\/jats:sup>Ga]FAPI-based planning resulted in D100%\u2009=\u200997.2% and V95%\u2009=\u200998.8% for the [<jats:sup>18<\/jats:sup>F]FDG-MTV. [<jats:sup>18<\/jats:sup>F]FDG-based-planning resulted in D100%\u2009=\u200935.9% and V95%\u2009=\u200978.1% for [<jats:sup>68<\/jats:sup>Ga]FAPI-MTV. [<jats:sup>18<\/jats:sup>F]FDG-based-planning resulted only in 2 patients in V95%\u2009&gt;\u200995% for [<jats:sup>68<\/jats:sup>Ga]FAPI-MTV, and in 1 patient in D100%\u2009&gt;\u200997% for [<jats:sup>68<\/jats:sup>Ga]FAPI-MTV. GTV-coverage in terms of V95% was 76.4% by [<jats:sup>18<\/jats:sup>F]FDG-based-planning and 99.5% by [<jats:sup>68<\/jats:sup>Ga]FAPI-based-planning. Pretreatment [<jats:sup>68<\/jats:sup>Ga]FAPI-PET\/CT enhances radiation-treatment-planning in this particular group of patients. While perilesional and tumoral follow-up [<jats:sup>18<\/jats:sup>F]FDG-uptake behaved uniformly, perilesional and tumoral reaction may differ in follow-up [<jats:sup>68<\/jats:sup>Ga]FAPI-imaging. Complementary [<jats:sup>68<\/jats:sup>Ga]FAPI- and [<jats:sup>18<\/jats:sup>F]FDG-imaging enhance treatment-response-assessment.<\/jats:p>","DOI":"10.1038\/s41598-022-20447-6","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T18:02:40Z","timestamp":1664388160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["[68Ga]FAPI-PET\/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomas"],"prefix":"10.1038","volume":"12","author":[{"given":"Nika","family":"Guberina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"P\u00f6ttgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Guberina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Metzenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Mucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Rischpler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Indenk\u00e4mpen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Treckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"20447_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-015-0963-9","author":"K Kubota","year":"2015","unstructured":"Kubota, K. et al. Impact of FDG-PET findings on decisions regarding patient management strategies: A multicenter trial in patients with lung cancer and other types of cancer. Ann. Nucl. Med. https:\/\/doi.org\/10.1007\/s12149-015-0963-9 (2015).","journal-title":"Ann. Nucl. Med."},{"issue":"1","key":"20447_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","volume":"127","author":"U Nestle","year":"2018","unstructured":"Nestle, U. et al. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother. Oncol. 127(1), 1\u20135. https:\/\/doi.org\/10.1016\/j.radonc.2018.02.023 (2018).","journal-title":"Radiother. Oncol."},{"issue":"1","key":"20447_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2017.06.003","volume":"124","author":"D De Ruysscher","year":"2017","unstructured":"De Ruysscher, D. et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother. Oncol. 124(1), 1\u201310. https:\/\/doi.org\/10.1016\/j.radonc.2017.06.003 (2017).","journal-title":"Radiother. Oncol."},{"issue":"1","key":"20447_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13014-021-01904-4","volume":"16","author":"M Guberina","year":"2021","unstructured":"Guberina, M. et al. Patterns of nodal spread in stage III NSCLC: Importance of EBUS-TBNA and 18F-FDG PET\/CT for radiotherapy target volume definition. Radiat. Oncol. 16(1), 176. https:\/\/doi.org\/10.1186\/s13014-021-01904-4 (2021).","journal-title":"Radiat. Oncol."},{"key":"20447_CR5","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jamaoncol.2017.0982","volume":"3","author":"FM Kong","year":"2017","unstructured":"Kong, F. M. et al. Effect of midtreatment PET\/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: A phase 2 clinical trial. JAMA Oncol. 3, 1358\u20131365 (2017).","journal-title":"JAMA Oncol."},{"key":"20447_CR6","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/j.cllc.2018.05.002","volume":"19","author":"S Raman","year":"2018","unstructured":"Raman, S. et al. Rationale and protocol for a Canadian multicenter phase II randomized trial assessing selective metabolically adaptive radiation dose escalation in locally advanced non-small-cell lung cancer (NCT02788461). Clin. Lung Cancer 19, e699\u2013e770 (2018).","journal-title":"Clin. Lung Cancer"},{"issue":"15 Suppl","key":"20447_CR7","doi-asserted-by":"publisher","first-page":"8548","DOI":"10.1200\/JCO.2021.39.15_suppl.8548","volume":"39","author":"FMS Kong","year":"2021","unstructured":"Kong, F. M. S. et al. NRG-RTOG1106\/Acrin 6697; 2021 ASCO Meeting. J. Clin. Oncol. 39(15 Suppl), 8548 (2021).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"20447_CR8","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.2967\/jnumed.120.260646","volume":"62","author":"M Guberina","year":"2021","unstructured":"Guberina, M. et al. Prognostic value of post-induction chemotherapy volumetric PET\/CT parameters for stage IIIA\/B non-small cell lung cancer patients receiving definitive chemoradiotherapy. J. Nucl. Med. 62(12), 1684\u20131691. https:\/\/doi.org\/10.2967\/jnumed.120.260646 (2021).","journal-title":"J. Nucl. Med."},{"issue":"3","key":"20447_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2967\/jnumed.120.256271","volume":"62","author":"RJ Hicks","year":"2021","unstructured":"Hicks, R. J., Roselt, P. J., Kallur, K. G., Tothill, R. W. & Mileshkin, L. FAPI PET\/CT: Will it end the hegemony of 18F-FDG in oncology?. J. Nucl. Med. 62(3), 296\u2013302 (2021).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"20447_CR10","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12885-021-08026-w","volume":"21","author":"J Calais","year":"2021","unstructured":"Calais, J. et al. Phase 3 multicenter randomized trial of PSMA PET\/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol. BMC Cancer 21(1), 512. https:\/\/doi.org\/10.1186\/s12885-021-08026-w (2021).","journal-title":"BMC Cancer"},{"issue":"2","key":"20447_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2214\/AJR.18.19881","volume":"211","author":"Y Sanli","year":"2018","unstructured":"Sanli, Y. et al. Neuroendocrine tumor diagnosis and management: 68Ga-DOTATATE PET\/CT. AJR Am. J. Roentgenol. 211(2), 267\u2013277. https:\/\/doi.org\/10.2214\/AJR.18.19881 (2018).","journal-title":"AJR Am. J. Roentgenol."},{"issue":"1125","key":"20447_CR12","doi-asserted-by":"publisher","first-page":"20210275","DOI":"10.1259\/bjr.20210275","volume":"94","author":"CW Govaerts","year":"2021","unstructured":"Govaerts, C. W. et al. 11C-methyl-l-methionine PET measuring parameters for the diagnosis of tumour progression against radiation-induced changes in brain metastases. Br. J. Radiol. 94(1125), 20210275 (2021).","journal-title":"Br. J. Radiol."},{"issue":"1","key":"20447_CR13","doi-asserted-by":"publisher","first-page":"15666","DOI":"10.1038\/s41598-019-52279-2","volume":"9","author":"M Hotta","year":"2019","unstructured":"Hotta, M., Minamimoto, R. & Miwa, K. 11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: Radiomics approach with random forest classifier. Sci. Rep. 9(1), 15666. https:\/\/doi.org\/10.1038\/s41598-019-52279-2 (2019).","journal-title":"Sci. Rep."},{"key":"20447_CR14","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1073\/pnas.91.12.5657","volume":"91","author":"MJ Scanlan","year":"1994","unstructured":"Scanlan, M. J. et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. U.S.A. 91, 5657\u20135661 (1994).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"20447_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbapap.2020.140409","volume":"1868","author":"A \u0160imkov\u00e1","year":"2020","unstructured":"\u0160imkov\u00e1, A., Busek, P., Sedo, A. & Konvalinka, J. Molecular recognition of fibroblast activation protein for diagnostic and therapeutic applications. Biochim. Biophys. Acta Proteins Proteomics 1868, 14040929 (2020).","journal-title":"Biochim. Biophys. Acta Proteins Proteomics"},{"key":"20447_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel, F. L. et al. 68Ga-FAPI PET\/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J. Nucl. Med. 60, 386\u2013392 (2019).","journal-title":"J. Nucl. Med."},{"key":"20447_CR17","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2214\/AJR.18.19501","volume":"211","author":"K Ozturk","year":"2018","unstructured":"Ozturk, K., Gencturk, M., Caicedo-Granados, E., Li, F. & Cayci, Z. Utility of FDG PET\/CT in the characterization of sinonasal neoplasms: Analysis of standardized uptake value parameters. AJR Am. J. Roentgenol. 211, 1354\u20131360 (2018).","journal-title":"AJR Am. J. Roentgenol."},{"key":"20447_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.clon.2017.01.038","volume":"29","author":"JM Wilson","year":"2017","unstructured":"Wilson, J. M., Mukherjee, S., Brunner, T. B., Partridge, M. & Hawkins, M. A. Correlation of 18F-fluorodeoxyglucose positron emission tomography parameters with patterns of disease progression in locally advanced pancreatic cancer after definitive chemoradiotherapy. Clin. Oncol. (R Coll. Radiol.) 29, 370\u2013377 (2017).","journal-title":"Clin. Oncol. (R Coll. Radiol.)"},{"issue":"5","key":"20447_CR19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.ijrobp.2018.12.009","volume":"103","author":"RL Bakst","year":"2019","unstructured":"Bakst, R. L. et al. Perineural invasion and perineural tumor spread in head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 103(5), 1109\u20131124 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"20447_CR20","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.radonc.2021.04.016","volume":"160","author":"M R\u00f6hrich","year":"2021","unstructured":"R\u00f6hrich, M. et al. 68Ga-FAPI-PET\/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas\u2014Imaging analysis and histological validation. Radiother. Oncol. 160, 192\u2013201. https:\/\/doi.org\/10.1016\/j.radonc.2021.04.016 (2021).","journal-title":"Radiother. Oncol."},{"key":"20447_CR21","doi-asserted-by":"publisher","first-page":"8297","DOI":"10.1245\/s10434-021-10276-8","volume":"28","author":"QP Janssen","year":"2021","unstructured":"Janssen, Q. P. et al. Added value of radiotherapy following neoadjuvant FOLFIRINOX for resectable and borderline resectable pancreatic cancer: A systematic review and meta-analysis. Ann. Surg. Oncol. 28, 8297\u20138308. https:\/\/doi.org\/10.1245\/s10434-021-10276-8 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"20447_CR22","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.21873\/anticanres.15283","volume":"41","author":"F Pasqualetti","year":"2021","unstructured":"Pasqualetti, F. et al. Adjuvant radiotherapy in patients with pancreatic adenocarcinoma. Is it still appealing in clinical trials? A meta-analysis and review of the literature. Anticancer Res. 41, 4697\u20134704 (2021).","journal-title":"Anticancer Res."},{"key":"20447_CR23","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/jso.26313","volume":"123","author":"AD Nehlsen","year":"2021","unstructured":"Nehlsen, A. D. & Goodman, K. A. Controversies in radiotherapy for pancreas cancer. J. Surg. Oncol. 123, 1460\u20131466 (2021).","journal-title":"J. Surg. Oncol."},{"key":"20447_CR24","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/cncr.32756","volume":"126","author":"LT Tchelebi","year":"2020","unstructured":"Tchelebi, L. T. et al. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis. Cancer 126, 2120\u20132131 (2020).","journal-title":"Cancer"},{"key":"20447_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1080\/17474124.2021.1911645","volume":"15","author":"S Nara","year":"2021","unstructured":"Nara, S. et al. Role of adjuvant and neoadjuvant therapy for resectable biliary tract cancer. Expert Rev. Gastroenterol. Hepatol. 15, 537\u2013545 (2021).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"20447_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/MNM.0b013e328360668a","volume":"34","author":"SL Hu","year":"2013","unstructured":"Hu, S. L. et al. Role of SUVmax obtained by 18F-FDG PET\/CT in patients with a solitary pancreatic lesion: Predicting malignant potential and proliferation. Nucl. Med. Commun. 34, 533\u2013539 (2013).","journal-title":"Nucl. Med. Commun."},{"key":"20447_CR27","first-page":"721","volume":"42","author":"AC Buck","year":"2001","unstructured":"Buck, A. C. et al. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: Does in vivo FDG uptake correlate with proliferative activity?. J. Nucl. Med. 42, 721\u2013725 (2001).","journal-title":"J. Nucl. Med."},{"key":"20447_CR28","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1634\/theoncologist.2014-0356","volume":"20","author":"KM Cho","year":"2015","unstructured":"Cho, K. M. et al. Metabolic characteristics of advanced biliary tract cancer using 18F-fluorodeoxyglucose positron emission tomography and their clinical implications. Oncologist 20, 926\u2013933 (2015).","journal-title":"Oncologist"},{"key":"20447_CR29","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00259-019-4270-x","volume":"46","author":"M Guberina","year":"2019","unstructured":"Guberina, M. et al. Pretreatment metabolic tumour volume in stage IIIA\/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: Analysis of the ESPATUE randomized phase 3 trial. Eur. J. Nucl. Med. Mol. Imaging 46, 1439\u20131447 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"20447_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","volume":"21","author":"U Nestle","year":"2020","unstructured":"Nestle, U. et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): A multicentre, open-label, randomised, controlled trial. Lancet Oncol. 21(4), 581\u2013592 (2020).","journal-title":"Lancet Oncol."},{"key":"20447_CR31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil, C. et al. 68Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer. J. Nucl. Med. 60, 801\u2013805 (2019).","journal-title":"J. Nucl. Med."},{"issue":"3","key":"20447_CR32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00259-021-05522-w","volume":"49","author":"L Lan","year":"2022","unstructured":"Lan, L. et al. The potential utility of [68Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG. Eur. J. Nucl. Med. Mol. Imaging 49(3), 963\u2013979 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"12","key":"20447_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.924223","volume":"4","author":"J Wu","year":"2022","unstructured":"Wu, J. et al. Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in the evaluation of patients with newly diagnosed non-small cell lung cancer. Front. Oncol. 4(12), 924223. https:\/\/doi.org\/10.3389\/fonc.2022.924223 (2022).","journal-title":"Front. Oncol."},{"issue":"1","key":"20447_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","volume":"48","author":"H Chen","year":"2021","unstructured":"Chen, H. et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings. Eur. J. Nucl. Med. Mol. Imaging 48(1), 73\u201386. https:\/\/doi.org\/10.1007\/s00259-020-04940-6 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"12","key":"20447_CR35","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s00259-019-04478-2","volume":"46","author":"Y Luo","year":"2019","unstructured":"Luo, Y., Pan, Q. & Zhang, W. IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET\/CT. Eur. J. Nucl. Med. Mol. Imaging 46(12), 2625\u20132626. https:\/\/doi.org\/10.1007\/s00259-019-04478-2 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"20447_CR36","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262808","author":"L Kessler","year":"2021","unstructured":"Kessler, L. et al. Pitfalls and common findings in 68Ga-FAPI-PET\u2014A pictorial analysis. J. Nucl. Med. https:\/\/doi.org\/10.2967\/jnumed.121.262808 (2021).","journal-title":"J. Nucl. Med."},{"key":"20447_CR37","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young, H. et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 35, 1773\u20131782 (1999).","journal-title":"Eur. J. Cancer"},{"key":"20447_CR38","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","volume":"42","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis, C. et al. Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: Preliminary results of an ongoing study. Eur. J. Nucl. Med. Mol. Imaging 42, 386\u2013396 (2015).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"Suppl 1","key":"20447_CR39","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50(Suppl 1), 122S-150S. https:\/\/doi.org\/10.2967\/jnumed.108.057307 (2009).","journal-title":"J. Nucl. Med."},{"issue":"2","key":"20447_CR40","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1269\/jrr.0631","volume":"48","author":"J Haveman","year":"2007","unstructured":"Haveman, J., Rodermond, H., van Bree, C., Wondergem, J. & Franken, N. A. Residual late radiation damage in mouse stromal tissue assessed by the tumor bed effect. J. Radiat. Res. 48(2), 107\u2013112 (2007).","journal-title":"J. Radiat. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20447-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20447-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20447-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T18:07:35Z","timestamp":1664388455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-20447-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["20447"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-20447-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"15 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T.S. receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Immunocore, Roche, Servier. His institution receives research funding from Bristol-Myers Squibb, Celgene, Roche; He holds ownership and serves on the Board of Directors of Pharma 15, all outside the submitted work. All authors declare that there is no conflict of interest concerning the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16261"}}